Skip to content
Screener

Neuropace, Inc. NPCE Q2 2025 earnings

Reported August 12, 2025 · After market close

Revenue$23.5MMiss by $913.1K
EPS-$0.26Miss by $0.02
Revenue estimate$24.4M
EPS estimate-$0.24

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$27.1M
EPS estimate-$0.11

Financials

Q2 2025

Income statement

See full
Revenue$19.5M+1.3%
Gross profit$16.2M+14.7%
Operating income-$8.2M-31.4%
Net income-$8.7M-15.1%
EPS (diluted)-$0.260.0%

Balance sheet

See full
Cash & equivalents$23.0M+77.2%
Total debt$71.5M-2.9%
Total equity$19.4M+96.6%
Total assets$106.1M+12.4%

Cash flow

See full
Operating cash flow-$2.1M+46.5%
CapEx$168.0K+167%
Free cash flow-$2.3M+43.1%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$352.91M+65.0%
Enterprise value$401.45M+46.2%
P/S4.2×+1.2×

Profitability

See full
Gross margin77.1%+2.9pp
Operating margin-25.1%-5.4pp
Net margin-30.7%-6.4pp
FCF margin-19.4%-3.1pp

Returns & leverage

See full
Return on equity-176.9%-13.0pp
Debt / equity3.7×-3.8×
Current ratio5.5×-0.9×

FAQ

When did Neuropace, Inc. report Q2 2025 earnings?
Neuropace, Inc. (NPCE) reported Q2 2025 earnings on August 12, 2025 after market close.
What were Neuropace, Inc.'s Q2 2025 revenue and EPS?
Neuropace, Inc. reported revenue of $23.5M and eps of $-0.26 for Q2 2025.
Did Neuropace, Inc. beat estimates in Q2 2025?
Revenue missed the consensus estimate of $24.4M by $913.1K. EPS missed the consensus estimate of $-0.24 by $0.02.
How did Neuropace, Inc.'s Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 22.1% from $19.3M a year earlier and eps grew 0.0% from $-0.26.
Where can I find Neuropace, Inc.'s Q2 2025 SEC filings?
You can read the 8-K earnings release (0001528287-25-000021) and the 10-Q periodic report (0001528287-25-000022) directly on SEC EDGAR. The filing index links above go to sec.gov.